Name:
5F–ADB; 5F–MDMB–PINACA (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)
Type:
Synthetic cannabinoid
AKA:
5F-ADB, 5F-MDMB-PINACA, (Positional isomer: 5F-AEB, 5F-EMB-PINACA), synthetic cannabinoids
5F–ADB; 5F–MDMB–PINACA (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) image
Synthetic substance, no natural derivative
IUPAC Logo
5F–ADB; 5F–MDMB–PINACA (Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate) image
5F-ADB, also known as 5F-MDMB-PINACA, is a synthetic cannabinoid first synthesized in the 2010s. It was designed to mimic the effects of THC and interact with cannabinoid receptors. Its appearance in synthetic cannabis products reflects ongoing trends in synthetic cannabinoid development. 5F-ADB's high potency and health risks have led to increased regulatory scrutiny and control measures.
Synthetic Substances Image
5F-ADB and 5F-MDMB-PINACA are synthetic cannabinoids with potent psychoactive effects. They act as uppers, producing altered perception and euphoria. Short-term use can lead to intense psychological effects, while long-term effects are not well documented. Overdose risks include severe psychological distress and potential toxicity. Safe use is uncertain due to limited research. Recent studies focus on their effects and associated health risks.
N/A
5F-ADB and 5F-MDMB-PINACA, synthetic cannabinoids, affect cannabinoid receptors, leading to altered mood and perception. Immediate effects include euphoria and relaxation, with long-term use potentially causing anxiety and cognitive impairments. Research focuses on their potency and psychological impact.
N/A
5F-ADB and 5F-MDMB-PINACA are synthetic cannabinoids with no historical lore but became known in the 21st century. Their cultural significance lies in their role as legal highs and the associated health risks. Proponents discuss their effects, while opponents highlight unpredictable effects and potential health dangers. Their use is primarily recreational, reflecting broader concerns about synthetic drug regulation.
N/A